دورية أكاديمية
أعرض في EDS

A Comprehensive Review of Use of Neurotoxins for Periocular Rejuvenation.

التفاصيل البيبلوغرافية
العنوان: A Comprehensive Review of Use of Neurotoxins for Periocular Rejuvenation.
المؤلفون: Konda SM; Duke Eye Center, Duke University Hospital, Durham, North Carolina., Woodward JA
المصدر: International ophthalmology clinics [Int Ophthalmol Clin] 2024 Jul 01; Vol. 64 (3), pp. 51-59. Date of Electronic Publication: 2024 Jun 24.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0374731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1536-9617 (Electronic) Linking ISSN: 00208167 NLM ISO Abbreviation: Int Ophthalmol Clin Subsets: MEDLINE
أسماء مطبوعة: Publication: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: Boston.
مواضيع طبية MeSH: Rejuvenation* , Neurotoxins*/therapeutic use, Humans ; Eyelids ; Cosmetic Techniques ; Skin Aging/drug effects
مستخلص: Competing Interests: J.A.W. has the following disclosures: Allergan—speaker consultant; Galderma—speaker consultant; Merz—consultant; Prollenium—speaker consultant; SkinCeuticals—speaker consultant; Stroma Medical—investor. S.M.K. has no conflicts of interest to disclose.
References: Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87:1044–1049.
Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol. 1992;18:17–21.
Yiannakopoulou E. Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. Pharmacology. 2015;95:65–69.
Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol. 2014;12:535–549.
Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol. 2001;8(Suppl 5):21–29.
Chen JJ, Dashtipour K. Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer. Pharmacotherapy. 2013;33:304–318.
Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29:1761–1768.
Feily A, Fallahi H, Zandian D, et al. A succinct review of botulinum toxin in dermatology; update of cosmetic and noncosmetic use. J Cosmet Dermatol. 2011;10:58–67.
Pirazzini M, Rossetto O, Eleopra R, et al. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69:200–235.
Binz T, Rummel A. Cell entry strategy of clostridial neurotoxins. J Neurochem. 2009;109:1584–1595.
Kaji R, Endo A, Sugawara M, et al. Efficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: a post-marketing observational study in Japan. eNeurologicalSci. 2021;25:100374.
Isaacson SH, Ondo W, Jackson CE, et al. Safety and efficacy of RimabotulinumtoxinB for treatment of sialorrhea in adults: a randomized clinical trial. JAMA Neurol. 2020;77:461–469.
Prager W, Bee EK, Havermann I, et al. Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study. Clin Interv Aging. 2013;8:449–456.
Gassner HG, Sherris DA. Addition of an anesthetic agent to enhance the predictability of the effects of botulinum toxin type A injections: a randomized controlled study. Mayo Clin Proc. 2000;75:701–704.
Haubner F. Simultaneous injection of lidocaine improves predictability of effect of botulinum toxin. Laryngorhinootologie. 2009;88:764; Simultane Injektion mit Lidocain verbessert die Vorhersehbarkeit des Effekts von Botulinumtoxin.
Kazim NA, Black EH. Botox: shaken, not stirred. Ophthalmic Plast Reconstr Surg. 2008;24:10–12.
Shome D, Nair AG, Kapoor R, et al. Botulinum toxin A: is it really that fragile a molecule? Dermatol Surg. 2010;36(Suppl 4):2106–2110.
Keen M, Kopelman JE, Aviv JE, et al. Botulinum toxin A: a novel method to remove periorbital wrinkles. Facial Plast Surg. 1994;10:141–146.
Blitzer A, Brin MF, Keen MS, et al. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg. 1993;119:1018–1022.
Garcia A, Fulton JE Jr. Cosmetic denervation of the muscles of facial expression with botulinum toxin. A dose-response study. Dermatol Surg. 1996;22:39–43.
Carruthers A, Carruthers J, Cohen J. Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter? Dermatol Surg. 2007;33(1 Spec No.):S97–S104.
Erickson BP, Lee WW, Cohen J, et al. The role of neurotoxins in the periorbital and midfacial areas. Facial Plast Surg Clin North Am. 2015;23:243–255.
Yang HM, Kim HJ. Anatomical study of the corrugator supercilii muscle and its clinical implication with botulinum toxin A injection. Surg Radiol Anat. 2013;35:817–821.
Wieder JM, Moy RL. Understanding botulinum toxin. Surgical anatomy of the frown, forehead, and periocular region. Dermatol Surg. 1998;24:1172–1174.
Dayan S, Yoelin SG, De Boulle K, et al. The psychological impacts of upper facial lines: a qualitative, patient-centered study. Aesthet Surg J Open Forum. 2019;1:ojz015.
Charles Finn J, Cox SE, Earl ML. Social implications of hyperfunctional facial lines. Dermatol Surg. 2003;29:450–455.
Coleman SR, Grover R. The anatomy of the aging face: volume loss and changes in 3-dimensional topography. Aesthet Surg J. 2006;26(1S):S4–S9.
Seo KK. Botulinum Toxin for Asians, 1st ed. Springer; 2017. 1 online resource (XVII, 182 pages 158 illustrations, 155 illustrations in color.
Kim H-J, Kim J, Lee H-K, et al. Clinical Anatomy of the Face for Filler and Botulinum Toxin Injection, 1st ed. Springer; 2016. 1 online resource (X, 179 pages 222 illustrations in color.
Ramey NA, Woodward JA. Mechanisms of blepharoptosis following cosmetic glabellar chemodenervation. Plast Reconstr Surg. 2010;126:248e–249e.
Lehrer MS, Benedetto AV. Botulinum toxin—an update on its use in facial rejuvenation. J Cosmet Dermatol. 2005;4:285–297.
Cotofana S, Freytag DL, Frank K, et al. The bidirectional movement of the frontalis muscle: introducing the line of convergence and its potential clinical relevance. Plast Reconstr Surg. 2020;145:1155–1162.
Swift A, Green JB, Hernandez CA, et al. Tips and tricks for facial toxin injections with illustrated anatomy. Plast Reconstr Surg. 2022;149:303e–312e.
Ahn BK, Kim YS, Kim HJ, et al. Consensus recommendations on the aesthetic usage of botulinum toxin type A in Asians. Dermatol Surg. 2013;39:1843–1860.
Huang W, Rogachefsky AS, Foster JA. Browlift with botulinum toxin. Dermatol Surg. 2000;26:55–60.
Frankel AS, Kamer FM. Chemical browlift. Arch Otolaryngol Head Neck Surg. 1998;124:321–323.
Yi KH, Lee JH, Kim GY, et al. Novel anatomical proposal for botulinum neurotoxin injection targeting lateral canthal rhytids. Toxins (Basel). 2022;14:462.
Park JT, Youn KH, Hur MS, et al. Malaris muscle, the lateral muscular band of orbicularis oculi muscle. J Craniofac Surg. 2011;22:659–662.
Matarasso SL. Complications of botulinum A exotoxin for hyperfunctional lines. Dermatol Surg. 1998;24:1249–1254.
Matarasso SL, Matarasso A. Treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids. Plast Reconstr Surg. 2001;108:208–214.
Manaloto RM, Alster TS. Periorbital rejuvenation: a review of dermatologic treatments. Dermatol Surg. 1999;25:1–9.
Flynn TC, Carruthers JA, Carruthers JA. Botulinum-A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. Dermatol Surg. 2001;27:703–708.
Ascher B, Talarico S, Cassuto D, et al. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)--Part II: Wrinkles on the middle and lower face, neck and chest. J Eur. Acad Dermatol Venereol. 2010;24:1285–1295.
Flynn TC, Carruthers JA, Carruthers JA, et al. Botulinum A toxin (BOTOX) in the lower eyelid: dose-finding study. Dermatol Surg. 2003;29:943–950; discussion 950-1.
França K, Castillo D, Lotti T. Non-cosmetic dermatological use of botulinum neurotoxin. Dermatol Ther. 2017;30:e12495.
Guida S, Farnetani F, Nistico SP, et al. New trends in botulinum toxin use in dermatology. Dermatol Pract Concept. 2018;8:277–282.
Kellogg DL Jr. In vivo mechanisms of cutaneous vasodilation and vasoconstriction in humans during thermoregulatory challenges. J Appl Physiol (1985). 2006;100:1709–1718.
Kellogg DL Jr, Pergola PE, Piest KL, et al. Cutaneous active vasodilation in humans is mediated by cholinergic nerve cotransmission. Circ Res. 1995;77:1222–1228.
Carmichael NME, Dostrovsky JO, Charlton MP. Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin. Pain. 2010;149:316–324.
Walker TJ, Dayan SH. Comparison and overview of currently available neurotoxins. J Clin Aesthet Dermatol. 2014;7:31–39.
Cote TR, Mohan AK, Polder JA, et al. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005;53:407–415.
Klein AW. Contraindications and complications with the use of botulinum toxin. Clin Dermatol. 2004;22:66–75.
Careta MF, Delgado L, Patriota R. Report of allergic reaction after application of botulinum toxin. Aesthet Surg J. 2015;35:NP102–NP105.
Small R. Botulinum toxin injection for facial wrinkles. Am Fam Physician. 2014;90:168–175.
المشرفين على المادة: 0 (Neurotoxins)
تواريخ الأحداث: Date Created: 20240624 Date Completed: 20240624 Latest Revision: 20240625
رمز التحديث: 20240625
DOI: 10.1097/IIO.0000000000000528
PMID: 38910505
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-9617
DOI:10.1097/IIO.0000000000000528